

REMARKS

Claims 2, 5, 10, 16, 18, 20, 34, 37, 39, 40, 50, 55 and 56 are present.

The invention in this application involves method of use claims 34, 36 and pharmaceutical combination Claim 37 and claims dependents thereon. These claims have been divided out of application Serial No. 10/081,075, now allowed.

The addition of R³ as polyhaloalkylaryloxycarbonyl in Claim 1 is based on original Claim 10, lines 29-30.

Claims 34 to 37 have been combined.

Claims 39, 42, 44 and 47 have been combined.

Claims 40, 43, 45, 48 and 49 have been combined.

Claims 50 and 51 have been combined.


Please note that the subject matter claimed herein has been divided out of parent application Serial No. 10/081,075.

Basis for new Claims 55 and 56 is found in the specification at page 81, line 22.

The compounds claimed in the method of use and pharmaceutical combination claims are those which have been claimed in parent application Serial No. 09/812,960, now U.S. Patent No. 6,414,002. Accordingly, it is submitted that the methods of use and combinations claimed herein which include the compounds in U.S. Patent No. 6,414,002 are patentable as well.

Accordingly, it is submitted that 2, 5, 10, 16, 18, 20, 34, 37, 39, 40, 50, 55 and 56 are patentable for the same reasons that the compounds of U.S. Patent No. 6,414,002 have been deemed patentable. Thus, it is believed that the above claims are in condition for allowance.

Respectfully submitted,



Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date:

Dec. 15, 2003